M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.
Michele Cavo,Sara Bringhen,Nicoletta Testoni,Paola Omedè,Giulia Marzocchi,Marina Ruggeri,Sandra Durante,Francesco Di Raimondo,Davide Rossi,Ausilia Gorgone,Francesca Patriarca,Maria Teresa Petrucci,Silvia Buttignol,Anna Levi,Massimo Offidani,Chiara Nozzoli,Roberto Ria,Barbara Olivero,Monica Galli,Vittorio Montefusco,Vincenzo Callea,Antonietta Falcone,Antonio De Vivo,Mario Boccadoro,Carolina Terragna,Antonio Palumbo +25 more
TL;DR: The combination of bortezomib with melphalan and prednisone, actually licensed as first-line therapy for MM patients who are not eligible for autologous stem-cell transplantation (ASCT), showed comparable activities in terms of time to progression and OS among patients with or without high-risk cytogenetic profiles.
Journal ArticleDOI
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito,Elena Zamagni,Concetta Conticello,Vincenzo Pavone,Salvatore Palmieri,Sara Bringhen,Monica Galli,Silvia Mangiacavalli,Daniele Derudas,Elena Rossi,Roberto Ria,Lucio Catalano,Paola Tacchetti,Giuseppe Mele,Iolanda Vincelli,Enrica Antonia Martino,Ernesto Vigna,Cirino Botta,Antonella Bruzzese,Anna Mele,Lucia Pantani,Serena Rocchi,Bruno Garibaldi,Nicola Cascavilla,Stelvio Ballanti,Giovanni Tripepi,Ferdinando Frigeri,Antonetta Pia Falcone,Clotilde Cangialosi,Giovanni Reddiconto,Giuliana Farina,Marialucia Barone,Ilaria Rizzello,Pellegrino Musto,Valerio De Stefano,Maurizio Musso,Maria Teresa Petrucci,Massimo Offidani,Antonino Neri,Nicola Di Renzo,Francesco Di Raimondo,Mario Boccadoro,Michele Cavo,Massimo Gentile +43 more
TL;DR: In this paper, the authors compared carfilzomib (K) versus elotuzumab (Elo) associated with lenalidomide and dexamethasone (Rd) for relapsed/refractory multiple myeloma.
Journal ArticleDOI
A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.
Antonio Palumbo,Cecilia Rus,Davide Rossi,Patrizia Pregno,Maria Teresa Ambrosini,Ilaria Avonto,Federica Cavallo,Massimo Iacobelli,Gianluca Gaidano,Constantine S. Mitsiades,Paul G. Richardson,Kenneth C. Anderson,Mario Boccadoro +12 more
TL;DR: Initial results suggest that MPTD is an effective oral salvage therapy with manageable toxicity and no DVT seen to date in pts with relapsed, refractory MM.
Journal ArticleDOI
Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22
Antonio Palumbo,Mario Boccadoro,Silvano Battaglio,Paolo Corradini,Bruna Giovinazzo,GC Avanzi,Giuseppe Ponzio +6 more
TL;DR: Data suggest the presence of a complex Ph translocation involving t(9;15;22)(q34.1 or q34.3;q26.1;q11 or q13) similar to findings in chronic myeloid leukemia.
Journal ArticleDOI
Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL).
Sergio Cortelazzo,Michele Magni,Milena Pintimalli,Michael Mian,Andrea Rossi,Atto Billio,Maddalena Marchesi,Manuela Zanni,Corrado Tarella,Mario Boccadoro,Angelo Andreini,Fabio Benedetti,Giovanni Pizzolo,Tiziano Barbui,Alessandro M. Gianni,Alessandro Rambaldi +15 more
TL;DR: It is concluded that R-HDS is an effective regimen for the induction of complete remissions in pts with newly diagnosed MCL and the manageable toxicity of the program in elderly pts proved that an age-adjusted R- HDS regimen can be safely applied to this age subgroup still producing long-term remissions.